Basal-like tumors are very similar to immunohistochemically defined triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). The international treatment guidelines focus on stage and on these molecular subtypes, which are characterized immunohistochemically as surrogate markers in clinical routine work. There has been substantial improvement in the prognosis and treatment of BC the prognosis depends mainly on the clinical stage, as well as the molecular characteristics of the tumor. In addition, the effect of pathological complete response on the prognosis does not depend on the treatment used.īreast cancer (BC) is the most frequent type of cancer in women, with approximately 70,000 new cases in Germany per year. This retrospective study of patients with triple-negative breast cancer adds to the evidence that the treatment effect of platinum may be greatest particularly in G3 tumors. Pathological complete response was a predictor for improved disease-free survival and overall survival in both treatment groups, with and without platinum chemotherapy. G3 ( P interaction = 0.013), and additional subgroup-specific differences were noted. The effect of neoadjuvant chemotherapy on pathological complete response was significantly different for G1–2 vs. A high histological grade (G3) was a predictor for higher pathological complete response in platinum-based therapy (OR 2.27 95% CI, 1.00 to 5.30).
41.8%), but this was not significant in the adjusted analysis (OR 1.44 95% CI, 0.68 to 3.09). The pathological complete response rate was higher after platinum/taxane treatment compared with anthracycline/taxane (50.0% vs. The impact of the pathological complete response rate on disease-free survival and overall survival was also analyzed. Pathological complete response was assessed relative to different treatments using logistic regression models with age, clinical tumor stage, grading, and Ki-67 as predictors and interaction terms, to obtain adjusted and subgroup-specific results. MethodsĪ total of 121 patients with triple-negative breast cancer received neoadjuvant treatment with either platinum or anthracycline between 20. This study investigates predictors of the response to neoadjuvant platinum-based or anthracycline-based treatment, and of the prognosis, in patients with triple-negative breast cancer. It has been reported that pathological complete response is an important surrogate marker for disease-free survival and overall survival in patients with triple-negative breast cancer.
0 kommentar(er)
